Compare Akamai Technologies, Inc. (AKAM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Akamai Technologies, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Akamai Technologies, Inc. trades at $116.57 (market cap $16.77B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.9× Akamai Technologies, Inc.'s market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Akamai Technologies, Inc. pays none. Which is the better fit depends on your goals.
| AKAM | REGN | |
|---|---|---|
Market Cap | $16.77B | $82.06B |
Sector | Technology | Health |
52-Week High | $161.14 | $812.27 |
52-Week Low | $71.97 | $555.51 |
Enterprise Value | $22.75B | $76.77B |
Dividend Yield | — | 0.47% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
